Frank Zenke

Alterations in the DDR machinery can give rise to cancer and at the same time represent a vulnerability that we aim to build on to develop safe and efficacious cancer therapies.

Over the past decade, my team and I have developed broad expertise and collaborations to tackle new DDR target classes, such as nucleases, helicases, and polymerases, and to perform translational research guiding the clinical strategy for our advanced DDR inhibitors.